



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/165	A1	(11) International Publication Number: WO 99/03460 (43) International Publication Date: 28 January 1999 (28.01.99)
(21) International Application Number: PCT/US98/14449 (22) International Filing Date: 15 July 1998 (15.07.98) (30) Priority Data: 60/052,684 15 July 1997 (15.07.97) US (71) Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC. [US/US]; Suite 600, 101 North Wilmot Road, Tucson, AZ 85711-3335 (US). (71)(72) Applicant and Inventor: HARRIS, Robert, H. [US/US]; 4 Winchester Lane, Holmdel, NJ 07733 (US). (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: AMINO ACID DERIVATIVES USEFUL TO TREAT STROKE (57) Abstract The invention provides a therapeutic method for treating or preventing stroke and other ischemic disorders, as well as novel compounds and pharmaceutical compositions useful for carrying out such methods.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AMINO ACID DERIVATIVES USEFUL TO TREAT STROKE

5

Background of the Invention

Stroke or cerebrovascular disease is the name for several disorders that occur within seconds or minutes after the blood supply to the brain is disturbed. Symptoms may progress or fluctuate during the first day or two after onset; this is called evolution. When no further deterioration occurs, the condition is considered to be a completed stroke. The only warning signal that suggests susceptibility to a stroke is a transient ischemic attack (TIA). Strokes are characterized by the location and type of disturbance. The most common disturbance is a deficient supply of blood through an artery (ischemia). When this happens, the nerve tissue served by that artery rapidly loses its ability to function and may die. The dead tissue is called an infarct.


Stroke is the third leading cause of death in developed countries. Approximately 300,000 Americans suffer a stroke each year; one-fourth of them die, and half the survivors have long-term disabilities, including paralysis of face or extremities, speech disorders, loss of bladder function, inability to swallow or dementia. Stroke is more likely to occur in the elderly, and the risk doubles each decade after age 35 years. Five percent of the population older than 65 years has had a stroke.

Due to the lack of available pharmacotherapeutic agents, a significant percentage of the population subject to stroke or its after-effects are poorly managed. None of the drugs presently available are capable of preventing damage due to stroke and most, such as anticoagulants, have disturbing side effects. Clearly, current therapy has failed to "seize control" of this debilitating pathology. There is currently a need for pharmaceutical agents and methods that are useful for the treatment and prevention of stroke.

30

Summary of the Invention

The invention provides the use of a compound of formula (I):



5 wherein

R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, lower cycloalkyl, lower cycloalkyl (lower alkyl), and R is unsubstituted or is substituted with at least one electron withdrawing group, or electron donating

10 group;

R₁ is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, (lower alkyl) heterocyclic, heterocyclic (lower alkyl), lower cycloalkyl, lower cycloalkyl (lower alkyl), each unsubstituted or substituted with an electron donating group or an electron withdrawing group

15 and

R₂ and R₃ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, lower cycloalkyl, lower cycloalkyl (lower alkyl), SO₃, or Z-Y wherein R₂ and R₃ may be unsubstituted or substituted with at least one

20 electron withdrawing group or electron donating group;

Z is O, S, S(O)_n, NR₄, PR₄ or a chemical bond;

Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic (lower alkyl), (lower alkyl)heterocyclic, cycloalkyl, cycloalkyl (lower alkyl) and Y may be

25 unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond;

or ZY taken together is NR₄NR₅R₇, NR₄OR₅, ONR₄R₇, OPR₄R₅, PR₄OR₅, SNR₄R₇, NR₄SR₇, SPR₄R₅, PR₄SR₇, NR₄PR₅R₆, PR₄NR₅R₇, NR₄C(O)R₅, SC(O)R₅, NR₄CO₂R₅, SCO₂R₅, NR₄C(O)R₅R₆, NR₄C(O)NR₅S(O)₂R₆,

30 NR₄C(S)R₅R₆, NR₄C(=Q)MNR₅C(=A)OR₆, or C(S)NH₂;

R₄, R₅ and R₆ are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, or lower alkynyl, wherein R₄, R₅ and R₆ may be

unsubstituted or substituted with an electron withdrawing group or an electron donating group;

R_7 is R_6 , $COOR_8$, or $C(O)R_8$;

R_8 is hydrogen or lower alkyl, or aryl (lower alkyl), and the aryl or alkyl group may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;

A and Q are independently O or S;

M is an alkylene chain containing up to 6 carbon atoms or a chemical bond;

n is 1-4; and

a is 1-3;

or a pharmaceutically acceptable salt thereof;

to prepare a medicament for treating or preventing stroke.

The invention also provides a therapeutic method comprising treating a human afflicted with, or at risk of stroke, by administering an effective amount of a compound of formula (I).

The invention also provides novel compounds of formula (I) or pharmaceutically acceptable salts thereof that can be used to treat the effects of stroke, as well as novel processes and intermediates that are useful to prepare the novel compounds of formula (I).

The invention also provides novel pharmaceutical compositions comprising compounds of Formula (I) that are useful for the treatment of stroke.

The methods, compounds and compositions of the invention are useful for the treatment or prevention of stroke, including the effects of impaired cerebral blood, such as cerebral hemorrhage, thrombosis or embolism. The term treatment (or treat) includes the amelioration of at least one of the effects of the acute phase of stroke or its after-effects, such as those described hereinabove. It is believed that the compounds of formula (I) function, at least in part, by reduction of the brain damage caused by cerebral ischemia and its after-effects.

Detailed Description of the Invention

The alkyl groups when used alone or in combination with other groups, are lower alkyl containing from 1 to 6 carbon atoms and may be straight chain or branched.

5 The aryl (lower alkyl) groups include, for example, benzyl, phenethyl, phenpropyl, phenisopropyl, phenbutyl, diphenylmethyl, 1,1-diphenylethyl, 1,2-diphenylethyl, and the like.

 The term aryl, when used alone or in combination, refers to an aromatic group which contains from 6 up to 18 ring carbon atoms and up to a total of 25
10 carbon atoms and includes the polynuclear aromatics. These aryl groups may be monocyclic, bicyclic, tricyclic or polycyclic and are fused rings. The term polynuclear aromatics is meant to encompass bicyclic, tricyclic fused aromatic ring system containing from 10-18 ring carbon atoms and up to a total of 25 carbon atoms. The aryl group includes phenyl, and the polynuclear aromatics,
15 e.g., naphthyl, anthracenyl, phenanthrenyl, azulenyl and the like. The aryl group also includes groups like ferrocenyl.

 Lower alkenyl is an alkenyl group containing from 2 to 6 carbon atoms and at least one double bond. These groups may be straight chained or branched and may be in the Z or E form. Such groups include vinyl, propenyl, 1-butenyl,
20 isobutenyl, 2-butenyl, 1-pentenyl, (Z)-2-pentenyl, (E)-2-pentenyl, (Z)-4-methyl-2-pentenyl, (E)-4-methyl-2-pentenyl, pentadienyl, e.g., 1,3 or 2,4-pentadienyl, and the like.

 The term cycloalkyl when used alone or in combination is a cycloalkyl group containing from 3 to 18 ring carbon atoms and up to a total of 25 carbon
25 atoms. The cycloalkyl groups may be monocyclic, bicyclic, tricyclic, or polycyclic and the rings are fused. The cycloalkyl may be completely saturated or partially saturated. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl, cyclooctenyl, cycloheptenyl, decalinyl, hydroindanyl, indanyl,
30 fenchyl, pinenyl, adamantyl, and the like. Cycloalkyl includes the cis or trans forms. Furthermore, the substituents may either be in endo or exo positions in the bridged bicyclic systems.

The term "electron-withdrawing and electron donating" refer to the ability of a substituent to withdraw or donate electrons relative to that of hydrogen if the hydrogen atom occupied the same position in the molecule. These terms are well understood by one skilled in the art and are discussed in

5 Advanced Organic Chemistry, by J. March, John Wiley and Sons, New York, NY, pp. 16-18 (1985). Electron withdrawing groups include halo, including bromo, fluoro, chloro, iodo and the like; nitro, carboxy, lower alkenyl, lower alkynyl, formyl, carboxyamido, aryl, quaternary ammonium, trifluoromethyl, aryl (lower alkanoyl), carbalkoxy and the like. Electron donating groups include such

10 groups as hydroxy, lower alkoxy, including methoxy, ethoxy and the like; lower alkyl, such as methyl, ethyl, and the like; amino, lower alkylamino, di(lower alkyl) amino, aryloxy such as phenoxy, mercapto, lower alkylthio, lower alkylmercapto, disulfide (lower alkyldithio) and the like. One skilled in the art will appreciate that the aforesaid substituents may have electron donating or

15 electron withdrawing properties under different chemical conditions. Moreover, the present invention contemplates any combination of substituents selected from the above-identified groups.

The term halo includes fluoro, chloro, bromo, iodo and the like.

The term acyl includes formyl and lower alkanoyl.

20 As employed herein, the heterocyclic substituent contains at least one sulfur, nitrogen or oxygen, but also may include more than one of N, S or non-peroxide O. The heterocyclic substituents contemplated by the present invention include heteroaromatics and saturated and partially saturated heterocyclic compounds. These heterocyclics may be monocyclic, bicyclic, tricyclic or

25 polycyclic and include fused rings. They may contain up to 18 ring atoms, up to a total of 17 ring carbon atoms and a total of up to 25 carbon atoms. The heterocyclics are also intended to include the so-called benzoheterocycles. Representative heterocyclics include furyl, thienyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, piperidyl,

30 pyrrolinyl, piperziny, quinolyl, triazolyl, tetrazolyl, isoquinolyl, benzofuryl, benzothienyl, morpholinyl, benzoxazolyl, tetrahydrofuryl, pyranyl, indazolyl, purinyl, indolinyl, pyrazolidinyl, imidazolinyl, imadazolidinyl, pyrrolidinyl,

furazanyl, N-methylindolyl, methylfuryl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridyl, 1,2-oxaethyl, aziridino, oxetanyl, azetidiny, the N-oxides of the nitrogen containing heterocycles, such as the nitric oxides of pyridyl, pyrazinyl, and pyrimidinyl and the like. The preferred heterocyclic are thienyl, furyl, pyrrolyl, benzofuryl, benzothienyl, indolyl, methylpyrrolyl, morpholinyl, pyridyl, tetrahydrofuranyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl. The preferred heterocyclic is a 5- or 6-membered heterocyclic compound. The especially preferred heterocyclic is furyl, pyridyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl. The most preferred heterocyclic is furyl and pyridyl.

10 The preferred compounds are those wherein n is 1, but di, tri and tetrapeptides are also contemplated to be within the scope of the claims.

The preferred values of R is aryl (lower alkyl), especially benzyl, and the preferred R₁ is H or lower alkyl. The most preferred R₁ group is methyl.

The most preferred electron donating substituents and electron withdrawing substituents are halo, nitro, alkanoyl, formyl, arylalkanoyl, aryloyl, carboxyl, carbalkoxy, carboxamide, cyano, sulfonyl, sulfoxide, heterocyclic, guanidine, quaternary ammonium, lower alkenyl, lower alkynyl, sulfonium salts, hydroxy, allyloxy, lower alkoxy, preferably methoxy or ethoxy, lower (alkyl), amino, (lower alkyl)amino, di(lower alkyl-)amino, (amino lower alkyl) mercapto, mercaptoalkyl, alkylthio; and alkylidithio. The term "sulfide" encompasses mercapto, mercapto alkyl and alkylthio, while the term disulfide encompasses alkylidithio. These preferred substituents may be substituted on any one of R₁, R₂, R₃, R₄, R₅ or R₆, R₇ or R₈ as defined herein.

The ZY groups representative of R₂ and R₃ include hydroxy, alkoxy, such as methoxy, ethoxy, aryloxy, such as phenoxy; thioalkoxy, such as thiomethoxy, thioethoxy; thioaryloxy such as thiophenyloxy; amino; alkyl-amino, such as methylamino, ethylamino; arylamino, such as anilino; lower dialkylamino, such as, dimethylamino; trialkyl ammonium salt, hydrazino, alkylhydrazino and arylhydrazino, such as N-methylhydrazino, N-phenylhydrazino, carbalkoxy hydrazino, aralkoxycarbonyl hydrazino, aryloxycarbonyl hydrazino, hydroxylamino, such as N-hydroxylamino (–NH–OH), lower alkoxy amino [(NHOR₁₈) wherein R₁₈ is lower alkyl], N-lower alkylhydroxyl amino [(NR₁₈)OH

wherein R_{18} is lower alkyl], N-lower alkyl-O-lower alkyl hydroxyamino, i.e.,
 $[N(R_{18})OR_{19}]$ wherein R_{18} and R_{19} are independently lower alkyl] and o-
 hydroxylamino ($-O-NH_2$); alkylamido such as acetamido, trifluoroacetamido,
 lower alkoxyamino, (e.g. $NH(OCH_3)$); and (heterocyclic)amino, such as
 5 pyrazoylamino.

The heterocyclic groups representative of R_2 and R_3 have the formula XI
 as disclosed in U.S. Pat. No. 5,378,729.

It is preferred that one of R_2 and R_3 is hydrogen.

In a preferred embodiment, one of R_2 and R_3 is hydrogen and that the
 10 other is (lower alkoxy)-lower alkyl or heterocyclic. It is preferred that one of R_2
 and R_3 is methoxymethyl or is a heterocyclic having Formula XI. The preferred
 heterocyclics include furyl, thienyl, benzothienyl, benzofuryl, oxazolyl, thiazolyl,
 isoxazolyl, indolyl, pyrazolyl, isoxazolidinyl, benzothienyl, benzofuryl,
 morpholinyl, indolyl, pyrrolyl, furfuryl, and methylpyrrolyl, pyridyl, pyrazinyl,
 15 imidazolyl, pyrimidinyl or pyridazinyl. In another preferred embodiment, one of
 R_2 and R_3 is alkyl (e.g., methylisopropyl), aryl (e.g., phenyl), 2-thiomethylethyl,
 lower alkoxy (e.g., ethoxy, methoxy), anilino, propenyl, alkyl-amino (e.g.,
 ethylamino or methylamino). In another preferred embodiment, one of R_2 and R_3
 is hydrogen and the other is heterocyclic lower alkyl, lower alkenyl, amino,
 20 lower alkoxy amino, N-lower alkylhydroxyamino, lower alkoxyamino, N-lower
 alkyl-O-lower alkylhydroxyamino or aralkoxycarbonylhydrazino.

A preferred compound that is useful to treat stroke is a compound of
 formula:



25 wherein

R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl
 (lower alkyl), heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic,
 lower cycloalkyl, lower cycloalkyl (lower alkyl), and R is unsubstituted or is
 substituted with at least one electron withdrawing group, or electron donating
 30 group;

R_1 is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl
 (lower alkyl), aryl, heterocyclic, (lower alkyl) heterocyclic, heterocyclic (lower

alkyl), lower cycloalkyl, lower cycloalkyl (lower alkyl), each unsubstituted or substituted with an electron donating group or an electron withdrawing group and

R_2 and R_3 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, lower cycloalkyl, lower cycloalkyl (lower alkyl), or Z-Y wherein R_2 and R_3 may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group;

Z is O, S, S(O), NR_4 , PR_4 or a chemical bond;

Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic (lower alkyl), (lower alkyl)heterocyclic and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond;

or ZY taken together is $NR_4NR_5R_7$, NR_4OR_5 , ONR_4R_7 , OPR_4R_5 , PR_4OR_5 , SNR_4R_7 , NR_4SR_7 , SPR_4R_5 , PR_4SR_7 , $NR_4PR_5R_6$, $PR_4NR_5R_7$, $NR_4C(O)R_5$, $SC(O)R_5$, $NR_4CO_2R_5$, SCO_2R_5 ;

R_4 , R_5 and R_6 are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, or lower alkynyl, wherein R_4 , R_5 and R_6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;

R_7 is R_6 , $COOR_8$, or $C(O)R_8$;


R_8 is hydrogen or lower alkyl, or aryl (lower alkyl), and the aryl or alkyl group may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;

n is 1-4; and

a is 1-3;

or a pharmaceutically acceptable salt thereof.

A preferred compound that is useful to treat stroke is a compound of formula:



wherein R_1 is H or lower alkyl, R_2 and R_3 are as defined above and A is hydrogen or an electron donating group or electron-withdrawing group and m is 0-5. It is preferred that A is hydrogen (i.e., $m = 0$). However, values of m equaling 1, 2 or 3 are also preferred.


- 5 A preferred compound that is useful to treat stroke is a compound of formula:



- wherein R and R_1 , independently, are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, or (lower alkyl) heterocyclic,
 10 each unsubstituted or substituted with at least one substituent;

- R_2 and R_3 , independently, are hydrogen, lower alkyl, lower alkenyl, lower alkyl heterocyclic, each unsubstituted or substituted with at least one substituent, preferably lower alkoxy; halogen or a heteroatom containing oxygen, nitrogen, sulfur or phosphorous substituted with hydrogen, lower alkyl or aryl, said lower
 15 alkyl or aryl groups being substituted or unsubstituted; and
 n is 1 to 4.

Another preferred compound that is useful to treat stroke is a compound of formula:



- 20 wherein R is aryl, aryl (lower alkyl), heterocyclic, (lower alkyl) heterocyclic, polynuclear aromatic or (lower alkyl) polynuclear aromatic, each unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent;

- R_1 is H or lower alkyl, such as methyl, unsubstituted or substituted with
 25 at least one electron withdrawing substituent or at least one electron donating substituent;

- R_2 and R_3 , independently, are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), heterocyclic, (lower alkyl) heterocyclic, polynuclear aromatic, (lower alkyl) polynuclear aromatic, each unsubstituted or
 30 substituted with at least one electron donating substituent, such as alkoxy; halogen or a heteroatom containing oxygen, nitrogen, sulfur or phosphorous

substituted with hydrogen, lower alkyl or aryl, said lower alkyl or aryl groups being substituted or unsubstituted; and

n is 1 to 4.

Another preferred compound that is useful to treat stroke is a compound
5 of formula:




wherein R is aryl (lower alkyl), heterocyclic, (lower alkyl) heterocyclic, polynuclear aromatic or (lower alkyl) polynuclear aromatic, each of which may be unsubstituted or substituted with at least one halo, nitro, acyl, carboxyl,
10 carboalkoxy, carboxamide, cyano, sulfonyl, sulfoxide (sulfinyl), heterocyclic, guanidine, quaternary ammonium hydroxy, alkoxy, alkyl, amino, phenoxy, mercapto, sulfide or disulfide;

R₁ is H or lower alkyl which may be unsubstituted or substituted with at least one halo, nitro, acyl, carboxamide, cyano, sulfonyl, sulfoxide (sulfinyl),
15 heterocyclic, guanidine, quaternary ammonium, hydroxy, lower alkoxy, amino, phenoxy, sulfide, or disulfide;

R₂ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, heterocyclic, (lower alkyl) heterocyclic, polynuclear aromatic, (lower alkyl) polynuclear aromatic, each unsubstituted or substituted with at least one electron
20 withdrawing substituent or at least one electron donating substituent; halogen or a heteroatom consisting of oxygen, nitrogen, sulfur or phosphorous, said heteroatom being substituted with hydrogen, lower alkyl or aryl, said lower alkyl or aryl groups being substituted or unsubstituted;

R₃ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl,
25 heterocyclic, (lower alkyl) heterocyclic, polynuclear aromatic, (lower alkyl) polynuclear aromatic, each unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent, such as alkoxy; halogen or a heteroatom consisting of oxygen, nitrogen, sulfur, or phosphorous, said heteroatom being substituted with hydrogen, lower alkyl or
30 aryl, said lower alkyl or aryl groups being substituted or unsubstituted;
and n is 1 to 4.

Another preferred compound that is useful to treat stroke is a compound of formula:



wherein R is aryl, aryl (lower alkyl), heterocyclic or heterocyclic (lower alkyl)

5 and R is unsubstituted or is substituted with at least one electron withdrawing group, or electron donating group;

R₁ is hydrogen or lower alkyl, unsubstituted or substituted with an electron donating group or an electron withdrawing group and

10 R₂ and R₃ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, heterocyclic (lower alkyl), or Z-Y wherein R₂ and R₃ may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group;

Z is O, S, S(O)_a, NR₄, PR₄ or a chemical bond;

15 Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, lower alkynyl, heterocyclic, heterocyclic (lower alkyl), or halo and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond, or

ZY taken together is NR₄NR₅R₇, NR₄OR₅, ONR₄R₇, OPR₄R₅, PR₄OR₅, SNR₄R₇, NR₄SR₇, SPR₄R₅, PR₄SR₇, NR₄PR₅R₆, PR₄R₅R₇.

20
$$\begin{array}{cccc} NR_4CR_5, & SCR_5, & NR_4COR_5, & SC-OR_5 \\ \parallel & \parallel & \parallel & \parallel \\ O & O & O & O \end{array}$$


R₄, R₅ and R₆ are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, or lower alkynyl, wherein R₄, R₅ and R₆ may be 25 unsubstituted or substituted with an electron withdrawing group or an electron donating group, and

R₇ is R₆ or COOR₈ or COR₈, R₈ is hydrogen or lower alkyl, or aryl (lower alkyl), wherein the aryl or lower alkyl groups may be unsubstituted or substituted with an electron withdrawing or electron donating group,

30 n is 1-4 and

a is 1-3.

Another preferred compound that is useful to treat stroke is a compound of formula:



wherein R is aryl, aryl lower alkyl, heterocyclic or heterocyclic alkyl which is unsubstituted or substituted with at least one electron withdrawing group or at least one electron donating group;

- 5 R_1 is hydrogen or lower alkyl which is unsubstituted or substituted with at least one electron withdrawing group or one electron donating group,

R_2 and R_3 are independently hydrogen, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), Z-Y, or a heterocyclic group which may be unsubstituted or substituted with at least one electron withdrawing or one electron donating

- 10 group, with the proviso that R_2 and R_3 cannot both be hydrogen;

Z is O, S, NR_4 , PR_4 or a chemical bond;

Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, lower alkynyl or halo, and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo,

- 15 Z is a chemical bond; or

ZY taken together is $NR_4NR_5R_6$, NR_4OR_5 , ONR_4R_5 , OPR_4R_5 , PR_4OR_5 , SNR_4R_5 , NR_4SR_5 , SPR_4R_5 , PR_4SR_5 , $NR_4PR_5R_6$, $PR_4NR_5R_6$,

R_4 , R_5 and R_6 are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, or lower alkynyl, wherein R_4 , R_5 and R_6 may be

- 20 unsubstituted or substituted with an electron withdrawing group or an electron donating group;

n is 1-4.

It is especially preferred that n is 1.

Another preferred compound that is useful to treat stroke is a compound

- 25 wherein R is aryl, aryl (lower alkyl), such as benzyl; heterocyclic, or heterocyclic (lower alkyl), R_1 is hydrogen or lower alkyl, such as methyl; R_2 and R_3 are independently hydrogen, heterocyclic, lower alkyl, aryl, lower alkoxy, lower alkoxy (lower alkyl), lower alkenyl, amino, hydroxylamino, lower alkoxy amino, N-lower alkyl hydroxy-amino, N-lower alkyl-O-lower alkyl hydroxyamino,
- 30 aralkoxy carbonyl hydrazino or alkylmercapto, and n is 1.

Another preferred compound that is useful to treat stroke is a compound

wherein n is 1, R and R_1 are as defined hereinabove and one of R_2 and R_3 is

hydrogen and the other is heterocyclic, heterocyclic (lower alkyl), aryl N-hydroxyamino, lower alkoxyamino, N-lower alkylhydroxylamino, N-lower alkyl-O-lower alkylhydroxyamino.

Another preferred compound that is useful to treat stroke is a compound
5 wherein n is 1, R and R_1 are as defined hereinabove, one of R_2 and R_3 is as defined hereinabove or the other is heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, aryl, N-hydroxylamino, lower alkoxy amino, N-lower alkyl hydroxylamino, N-lower alkyl-O-lower alkyl hydroxylamino, lower alkoxy, dialkyl lower amino, lower alkylamino, aryl lower alkylcarbonyl hydrazino, or
10 lower alkylmercapto.

Another preferred compound that is useful to treat stroke is a compound wherein R_2 is hydrogen; and R_3 is 2-furyl, 2-pyrrolyl, 1-pyrazolyl, 2-oxazolyl, 2-thiazolyl, pyridyl, pyrazinyl, or pyrimidinyl.

Another preferred compound that is useful to treat stroke is a compound
15 wherein R_2 is hydrogen; R_3 is NR_4OR_5 , R_4 is hydrogen or lower alkyl; and R_5 is lower alkyl.


Another preferred compound that is useful to treat stroke is a compound wherein R is benzyl, substituted with at least one electron withdrawing substituent or at least one electron donating substituent.

20 The various combination and permutations of the Markush groups of R_1 , R_2 , R_3 , R and n described herein are contemplated to be within the scope of the present invention. Moreover, the present invention also encompasses compounds and compositions which contain one or more elements of each of the Markush groupings in R_1 , R_2 , R_3 , n and R and the various combinations thereof.
25 Thus, for example, the present invention contemplates that R_1 may be one or more of the substituents listed hereinabove in combination with any and all of the substituents of R_2 , R_3 and R with respect to each value of n .

The compounds of the present invention may contain one (1) or more asymmetric carbons and may exist in racemic and optically active forms. The
30 configuration around each asymmetric carbon can be in either the D or L form. (It is well known in the art that the configuration around a chiral carbon atoms can also be described as R or S in the Cahn-Prelog-Ingold nomenclature system).

All of the various configurations around each asymmetric carbon, including the various enantiomers and diastereomers as well as racemic mixtures and mixtures of enantiomers, diastereomers or both are contemplated by the present invention.

In the principal chain, there exists asymmetry at the carbon atoms to which the groups R_2 and R_3 are attached as substituted. When n is 1, the compounds of the present invention is of the formula:



wherein R , R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , Z and Y are as defined previously, and $C(O)$ represents a carbonyl group. As used herein, the term configuration shall refer to the configuration around the carbon atom to which R_2 and R_3 are attached, even though other chiral centers may be present in the molecule. Therefore, when referring to a particular configuration, such as D or L, it is to be understood to mean the stereoisomer, including all possible enantiomers and diastereomers. The compounds of the present invention are directed to all of the optical isomers, i.e., the compounds of the present invention are either the L stereoisomer or the D-stereoisomer. These stereoisomers may be found in mixtures of the L and D stereoisomer, e.g., racemic mixtures. The D stereoisomer or R configuration is preferred.

The present compounds can be prepared in accord with Scheme I-VI and the working examples of U.S. Pat. No. 5,378,729, and as disclosed by D. Choi et al., *J. Med. Chem.*, **39**, 1907 (1996), P. Bardel et al., *J. Med. Chem.*, **37**, 4567 (1994) and H. Kohn et al., *J. Med. Chem.*, **33**, 919 (1990).

The compounds can also be prepared using procedures described in U.S. Patent No. 5,654,301. In particular, these procedures can be used to prepare compounds wherein Q or A is thioxo (=S).

Resulting mixtures of isomers can be separated in the pure isomers by methods known to one skilled in the art, e.g., by fractional distillation, crystallization and/or chromatography. Optically pure functionalized amino acid derivatives can be prepared directly from the corresponding pure chiral intermediate, such as an optically active amino acid. Racemic products can likewise be resolved into the optical antipodes, for example, by separation of diastereomeric salts thereof, e.g., by fractional crystallization, by selective

enzymatic hydrolysis, e.g., papain digestion, or by use of a chiral stationary phase in chromatography (HPLC). For a discussion of chiral stationary phases for HPLC, See, DeCamp, Chirality, 1, 2-6 (1989).

For example, a racemic mixture of any of the intermediate in any of the
5 schemes, wherein R_1 is H is reacted with an optically active amine, RNH_2 , e.g., (R)(+) α -methyl-benzylamine to form a pair of diastereomeric salts.

Diastereomers can then be separated by recognized techniques known in the art, such as fractional recrystallization and the like.

In another method, a racemic mixture of final products or intermediates
10 can be resolved by using enzymatic methods. Since enzymes are chiral molecules, an optically pure enzyme can be used to separate the racemic mixture, since it will preferentially act on one of the compounds, without affecting the enantiomer. For example, acylase, such as acylase I, can be used to separate the racemic modification of an intermediate D,L(\pm) α -acetamido-2-furanacetic acid.
15 It acts on the L(\pm) α -acetamido-2-furanacetic acid, but will not act on the D enantiomer. In this way, the D(-) α -acetamido-2-furanacetic acid can be isolated. The intermediate can then react with the amine (RNH_2) under amide forming conditions as described hereinabove to form the compound of Formula (I).

In cases where compounds are sufficiently basic or acidic to form stable
20 nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α -ketoglutarate, and α -glycerophosphate.
25 Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.

Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically
30 acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.

The compounds of formula (I) can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of unit dosage or sustained release forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intrathecal, 5 intramuscular, topical or subcutaneous routes.

Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle or carrier such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be 10 incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The 15 percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.

The tablets, troches, pills, capsules, and the like may also contain the 20 following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring 25 may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and 30 the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in

preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices, such as patches or implantable depots or pumps.

- 5 The active compound may also be administered intravenously, intrathecally, intraperitoneally, or by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary
10 conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

- The pharmaceutical dosage forms suitable for injection, inhalation, insufflation or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the
15 extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes or biodegradable polymeric microparticles. In all cases, the ultimate dosage form must be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example,
20 water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action
25 of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of
30 agents delaying absorption, for example, aluminum monostearate and gelatin.

 Sterile injectable or infusable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various

of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus
5 any additional desired ingredient present in the previously sterile-filtered solutions.

The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage
10 form can, for example, contain the principal active compound in amounts ranging from about 5 to about 1000 mg, with from about 250 to about 750 mg being preferred. Expressed in proportions, the active compound is generally present in from about 10 to about 750 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are
15 determined by reference to the usual dose and manner of administration of the said ingredients.

The active ingredients of the therapeutic compositions and the compounds of the present invention can exhibit anti-stroke activity when administered in amounts ranging from about 1 mg to about 100 mg per kilogram
20 of body weight per day. A preferred dosage regimen for optimum results would be from about 10 mg to about 50 mg per kilogram of body weight per day, and such dosage units are employed that a total of from about 0.5 gram to about 3.0 grams of the active compound for a subject of about 70 kg of body weight are administered in a 24-hour period. This dosage regimen may be adjusted to
25 provide the optimum therapeutic response and is preferably administered one to three times a day in dosages of about 600 mg per administration. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A decided practical advantage is that the active compound may be administered
30 in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular or subcutaneous routes.

Useful dosages of the compounds of formula I can be determined by comparing their *in vitro* activity, and *in vivo* activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.

- 5 The invention will be further described by reference to the following detailed examples, wherein full spectral data are available in D. Choi et al., J. Med. Chem., **39**, 1907 (1996)

Example 1

- Synthesis of (S)-enriched N-Benzyl-2-aminohydracrylamide ((S)-7). To
10 a stirred methanolic solution (250 mL) of L-serine methyl ester hydrochloride ((S)-6) (20.00 g, 128 mmol) was added benzylamine (55.9 mL, 512 mmol), and then the reaction solution was heated at reflux (18 h). The solvent was removed under reduced pressure, the insoluble salts were filtered, and the excess benzylamine was removed under high vacuum (Kugelrohr). The residue was
15 dissolved in H₂O (100 mL), and the product was extracted with CHCl₃ (8 x 200 mL). The organic layers were combined and dried (Na₂SO₄), and the solvent was removed under reduced pressure. The residue was triturated with Et₂O (150 mL) and filtered to give 8.50 g (34%) of the product as a white solid: mp 76-80°C.

Example 2

- Synthesis of (R)-enriched N-Benzyl-2-aminohydracrylamide ((R)-7). HCl
20 (8.00 g, 219.4 mmol) was passed into MeOH (250 mL), and then D-serine ((R)-5) (20.00 g, 190.3 mmol) was added. The reaction solution was heated at reflux (18 h), then benzylamine (81.6 mL, 761 mmol) was added, and then the reaction mixture was heated for additional 18 h. The solvent was removed under reduced
25 pressure, the insoluble salts were filtered, and the excess benzylamine was removed under high vacuum (Kugelrohr). The residue was dissolved in H₂O (100 mL), and the product was extracted with CHCl₃ (8 x 200 mL). The organic layers were combined and dried (Na₂SO₄), and the solvent was removed under reduced pressure. The residue was triturated with Et₂O (150 mL) and filtered to
30 vie 10.0 g (27%) of the product as white solid: mp 74-78°C; [α]_D²³ (c = 1, MeOH) = 1.6°.

Example 3

Synthesis of (S)-N-Benzyl-2-acetamidohydracrylamide ((S)-9). To a stirred CH_2Cl_2 suspension (100 mL) of enriched (S)-7 (8.50 g, 43.7 mmol) was added Ac_2O (5.0 mL, 52.4 mmol), and then the reaction suspension was stirred at room temperature (1 h). The solvent was removed under reduced pressure to give a white solid. The product was triturated with Et_2O (250 mL) to give 8.50 g (82%) of enriched (S)-27 as a white solid. The reaction product was recrystallized (3 x) using EtOH to give 1.89 g (18%) of (S)-27: mp 147-148°C.

Example 4

Synthesis of (R)-N-Benzyl-2-acetamidohydracrylamide ((R)-9). Using the preceding procedure and enriched (R)-7 (10.00 g, 51.5 mmol) and Ac_2O (5.8 mL, 61.8 mmol) gave 7.60 g (62%) of enriched (R)-9 as a white solid. The reaction product was recrystallized (2x) using EtOH to give 3.50 g (29%) of (R)-27: mp 148-149°C; $[\alpha]_D^{23}$ ($c = 1$, MeOH) = +22.4°.

Example 5

Synthesis of (S)-N-Benzyl-2-acetamido-3-methoxypropionamide ((S)-1). To a stirred CH_3CN solution (300 mL) of (S)-9 (1.65 g, 7 mmol) were successively added Ag_2O (8.11 g, 35 mmol) and MeI (4.4 mL, 70 mmol) at room temperature. the reaction mixture was stirred at room temperature (4 d). The insoluble salts were filtered, and the solvents were removed *n vacuo* to give a white solid. The residue was triturated with Et_2O (100 mL) to give 1.40 g (80%) of (S)-1.

Example 6

Synthesis of (R)-N-Benzyl-2-acetamido-3-methoxypropionamide ((R)-1). Using the preceding procedure and (R)-9 (2.36 g, 10 mmol), Ag_2O (11.59 g, 50 mmol), and MeI (6.2 mL, 100 mmol) gave 2.20 g (88%) of (R)-1 after stirring at room temperature (4 d): mp 143-144°C; $[\alpha]_D^{23}$ ($c = 1$, MeOH) = +16.4°.

Example 7Pharmacological Studies

Studies were conducted to examine the possible therapeutic efficacy of compound (R)-1 in an animal model of induced focal brain ischemia (see A. Tamura et al., J. Cerebral Blood Flow and Metab., 1, 53 (1981); X. Cao et al.,

Brain Res., 644, 267 (1994)). The ischemic insult was effected by permanent unilateral occlusion of a middle cerebral artery in rats. This model is one of many that have been developed to mimic human stroke sequela and brain damage, and to evaluate the efficacy of potential therapies for the treatment of human stroke.

1. Drugs and Chemicals

Chloral hydrate (Sigma, St. Louis, MO 63178 USA), MK-801 (RBI, Natick MA 01760-2447 USA), Kanamycin (Sigma, St. Louis, MO 63178 USA), 10% Povidone iodine solution (T. K., Taiwan), Pyrogen free saline (Astar, Taiwan) and 2% Crystal Violet (Delta, Taiwan) were used.

2. Equipment

Dental drill (UPOWER UG 33, SELECTOR-M), Image Analyzer (Life Science Resources VISTA Version 3.0), Infant Incubator (Brighten Life BL-90-SC), Magnifying stereomicroscope (ZEISS, Stemi 1000), Microscissors (A. Heiss), Microtome (SHANDON, Varistain 24-4 Automatic Slide), Microinjection Pump (Syringe Driver-Type MS16A Graseby Medical) and Rectal thermistor probe (Harvard Hemeothermic Blanket Control Unit) were used.

3. Animals

Male Wistar rats weighing 150-200 gms (10 weeks of age) from the Animal Resources Center, medical College of National Taiwan University were used. The animals were housed separately in positive pressure stainless steel isolation racks (NuAire®, Mode: NU-605, airflow velocity 50 ± 5 ft/min, HEPA Filter). APEC® cages contained 6 rats (in cm, 45 length x 23 width x 15 height). The animals were maintained in a controlled temperature (22°-24°C) and humidity (60%-80%) environment with 12 hour light dark cycles for at least one week in the laboratory prior to use. Free access to standard lab chow (Fwusow Industry Limited Co.) and tap water was granted. All aspects of this work, i.e., housing, experimentation and disposal of animals were performed in general accordance with the International Guiding Principles for Biomedical Research Involving Animals (CIOMS Publication No. ISBN 92 90360194, 1985).

4. Methods

The permanent brain ischemia via middle cerebral artery occlusion (MCAO) was carried out under general anesthesia induced by chloral hydrate (500 mg/10 ml/kg i.p.). The temporoparietal region was shaved and a skin incision was made between the lateral aspect of the orbit and the external acoustic meatus. The superior pole of the parotid gland was reflected downwards as was the temporalis muscle after partial resection of its cranial insertion. The distal course of the middle cerebral artery was then visible through the translucent skull.

Under a 10x magnifying stereomicroscope (ZEISS, Stemi 1000), a craniectomy was performed with a dental drill and then enlarged with fine synovectomy rongeurs. The exposed middle cerebral artery was cut with microscissors and the temporalis and parotid gland were replaced. The incision area was lightly dusted with kanamycin (Sigma, St. Louis, MO 63178 USA), the scalp was sutured and a 10% povidone iodine solution (T. K., Taiwan) was topically applied. During surgery, the animals were maintained normothermic ($37.5 \pm 1.0^{\circ}\text{C}$) by means of a homeothermic heating system coupled to a rectal thermistor probe (Harvard Homeothermic Blanket Control Unit). Following surgery, the animals were kept normothermic in an Infant Incubator (Brighten Life BL-90-SC) for about 1 hour while recovering from anesthesia. After recovery, the rats were housed 5 per cage with free access to food and water and kept in a clean animal room.

The test compound (*R*)-1 was administered to rats 15 minutes before occlusion at a dose of 25 mg/kg IP followed by 5 mg/kg/hour IV infusion for 4 hours. The reference agent MK-801 was also administered 15 minutes before occlusion at a dose of 0.5 mg/kg IP followed by 0.5 mg/kg/4 hours IV infusion. Vehicle (PBS, pH 7.4) was similarly administered at a volume of 5 ml/kg IP 15 minutes before occlusion followed by 5 ml/kg/4 hour IV infusion. Body temperature was recorded at pretreatment of test substances and at 30 minutes after IP injection as well as 30 minutes after IV (4 hours) perfusion.

On the fourth day after the ischemic insult, the animals were sacrificed by decapitation. Their brains were rapidly removed and frozen at -70°C in a deep

freezer. Twenty-four hours later, whole brain coronal sections (20 μ m) were sliced by microtome ("SHANDON" Varistain 24-4 Automatic Slide). Every 20th section (i.e., 400 μ m apart) was selected for histological examination. Altogether thirty slices, stained by 2% crystal violet, were used to measure the area of ischemia damage. This was quantitatively assessed by an Image Analyzer (Life Science Resources VISTA Version 3.0). The total ischemic area (mm^2) of each coronal slice from each animal was accumulated and expressed as the mean \pm S.E.M. The calculated infarcted volume (mm^3 in total distance of 12 mm) of focal cerebral ischemia was expressed as the mean \pm S.E.M. for each experimental group. The percent protection obtained for each test substance treated group compared to the vehicle treated group was also calculated.

5. Results

Under these experimental conditions, MCAO caused a reproducible ischemia of about 20%-25% of the affected hemisphere. For the most part, the area of damage was largely continued to various cortical regions (i.e., frontal, sensorimotor, auditory and occipital cortices) and only rarely involved damage to components of the basal ganglia. The area of infarct was quantitatively assessed in 30 anterior to posterior coronal slices for each animal. Compound (R)-1 (total dose of 1 mg/kg) reduced the total infarct volume by $75.3 \pm 7.1\%$; however, 1 out of 5 tested animals were dead within 72 hours after MK-801 treatment. Compound (R)-1 (total dose of 45 mg/kg) significantly reduced the total infarct volume by $72.8 \pm 6.8\%$ ($n = 5$); no mortality was seen in these animals. These results are summarized on Table 1, below.

25

Table 1

Effect of (R)-1 and MK-801 relative to Vehicle on the
Total Volume of Ischemic Lesions in the Brains of MCAO Rats

	Compound	Route	Dose	N	Infarcted ($\bar{X} \pm \text{SEM mm}^2$)	% Inh. ($\bar{X} \pm \text{SEM}$)
30	Vehicle (PBS)	IP/IV	5 ml/kg	5	83.52 ± 11.29	—
	MK-801	IP/IV	*1 mg/kg	5	20.61 ± 5.83	75.3 ± 7.11
	(R)-1	IP/IV	45 mg/kg	5	22.49 ± 5.71	72.8 ± 6.8

*1 out of 5 animals were dead 71 hours after MK-801 treatment at dose of 0.5 mg/kg, i.p. and 0.5 mg/kg/4 hours i.v. infusion.

5

These studies confirm the neuroprotective effect previously observed for MK-801 in this rat model of brain focal ischemia induced by permanent, unilateral middle cerebral artery occlusion. The test compound, (*R*)-1, revealed a similar and significant neuroprotective effect in this model. No significant
10 changes in body temperature were seen during or at 30 minutes after compound administration.

While the invention has been described with reference to certain preferred embodiments, those skilled in the art will realize that changed and modifications may be made thereto without departing from the full and intended
15 scope of the appended claims. All patent documents and publications cited hereinabove are incorporated by reference herein.

What Is Claimed Is:

1. The use of a compound of formula formula (I):



wherein

R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, lower cycloalkyl, lower cycloalkyl (lower alkyl), and R is unsubstituted or is substituted with at least one electron withdrawing group, or electron donating group;

R₁ is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, (lower alkyl) heterocyclic, heterocyclic (lower alkyl), lower cycloalkyl, lower cycloalkyl (lower alkyl), each unsubstituted or substituted with an electron donating group or an electron withdrawing group and

R₂ and R₃ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, lower cycloalkyl, lower cycloalkyl (lower alkyl), SO₃, or Z-Y wherein R₂ and R₃ may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group;

Z is O, S, S(O)_n, NR₄, PR₄ or a chemical bond;

Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic (lower alkyl), (lower alkyl)heterocyclic cycloalkyl, cycloalkyl (lower alkyl) and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond;

or ZY taken together is NR₄NR₅R₇, NR₄OR₅, ONR₄R₇, OPR₄R₅, PR₄OR₅, SNR₄R₇, NR₄SR₇, SPR₄R₅, PR₄SR₇, NR₄PR₅R₆, PR₄NR₅R₇, NR₄C(O)R₅, SC(O)R₅, NR₄CO₂R₅, SCO₂R₅, NR₄C(O)R₅R₆, NR₄C(O)NR₅S(O)_nR₆, NR₄C(S)R₅R₆, NR₄C(=Q)MNR₅C(=A)OR₆, or C(S)NH₂;

R_4 , R_5 and R_6 are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, or lower alkynyl, wherein R_4 , R_5 and R_6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;

5 R_7 is R_6 , COOR_8 , or C(O)R_8 ;

R_8 is hydrogen or lower alkyl, or aryl (lower alkyl), and the aryl or alkyl group may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;

A and Q are independently O or S;

10 M is an alkylene chain containing up to 6 carbon atoms or a chemical bond;

n is 1-4; and

a is 1-3;

or a pharmaceutically acceptable salt thereof;

15 to prepare a medicament for treating or preventing stroke.

2. The use of a compound of formula:



wherein

20 R is aryl, aryl (lower alkyl), heterocyclic (lower alkyl), lower alkyl, or heterocyclic, each unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent;

R_1 is H or lower alkyl, unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent;

25

R_2 and R_3 , independently, are hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), heterocyclic (lower alkyl), or heterocyclic, each unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent; halogen or are oxygen, nitrogen, or sulfur substituted with hydrogen, lower alkyl or aryl, said lower alkyl or aryl groups being substituted or unsubstituted; and

30

n is 1 to 4;

or a pharmaceutically acceptable salt thereof;

to prepare a medicament for treating or preventing stroke.

5 3. The use of claim 1 or 2 wherein R is aryl (lower alkyl), heterocyclic (lower alkyl) or heterocyclic, each of which may be unsubstituted or substituted with at least one halo, nitro, acyl, carboxyl, carboalkoxy, carboxamide, cyano, sulfonyl, sulfoxide, heterocyclic, guanidine, quaternary ammonium, hydroxy, lower alkoxy, lower alkyl, amino, or phenoxy;

10 R₁ is H or lower alkyl which may be unsubstituted or substituted with at least one halo, nitro, acyl, carboxamido, cyano, sulfonyl, sulfoxide, heterocyclic, guanidine, ammonium, hydroxy, lower alkoxy, amino, or phenoxy;

15 R₂ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, heterocyclic (lower alkyl), or heterocyclic, each unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent; or R₂ is halogen or nitrogen, oxygen or sulfur, each substituted with hydrogen, lower alkyl or aryl, said lower alkyl or aryl groups being substituted or unsubstituted;

20 R₃ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, heterocyclic (lower alkyl), or heterocyclic, each unsubstituted or substituted with at least one electron withdrawing substituent or at least one electron donating substituent; or

25 R₃ is halogen, or oxygen, nitrogen, or sulfur, each substituted with hydrogen, lower alkyl or aryl, said lower alkyl or aryl groups being substituted or unsubstituted, and n is 1-4.

4. The use of claim 1 or 2 wherein one of R₂ or R₃ is other than hydrogen.

30 5. The use of claim 1 or 2 wherein n is 1.

6. The use of claim 1 or 2 wherein n is 1; and one of R₂ and R₃ is hydrogen and the other is heterocyclic or (lower alkyl) heterocyclic.
7. The use of claim 1 or 2 wherein n is 1; and one of R₂ and R₃ is hydrogen
5 and other is (lower alkoxy) lower alkyl.
8. The use of claim claim 6 wherein one of R₂ and R₃ is hydrogen and the other is thienyl, furyl, pyrrolyl or phenyl.
- 10 9. The use of claim 1 or 2 wherein one of R₂ and R₃ is hydrogen and the other is lower alkenyl or lower alkynyl.
10. The use of claim 1 or 2 wherein one of R₂ and R₃ is hydrogen and the other is lower alkoxy.
- 15 11. The use of claim 1 or 2 wherein one of R₂ and R₃ is hydrogen and the other is lower alkyl.
12. The use of claim 1 or 2 wherein the medicament is a unit dosage form
20 containing from about 5 to about 1000 mg of said compound.
13. The use of claim 1 or 2 wherein R₁ is hydrogen, or R₁ is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, amyl or hexyl, unsubstituted or substituted with at least one electron withdrawing substituent or at least one
25 electron donating substituent.
14. The use of claim 13 wherein R₁ is methyl.
15. The use of claim 1 or 2 wherein R is benzyl, unsubstituted or substituted
30 with at least one electron withdrawing substituent or at least one electron donating substituent.

16. The use of claim 1 or 2 wherein said electron withdrawing substituent is halo, nitro, acyl, carboxyl, carboalkoxy, carboxamide, cyano, sulfonyl, sulfinyl, heterocyclic, guanidine or quaternary ammonium.
- 5 17. The use of claim 1 or 2 wherein said electron donating substituent is hydroxy, lower alkoxy, lower alkyl, amino or phenoxy.
18. The use of claim 1 or 2 wherein R is benzyl, R₁ is methyl, R₂ is hydrogen, R₃ is methyl and n is 1.
- 10 19. The use of claim 1 or 2 wherein R is benzyl, R₁ is methyl, R₂ is hydrogen, R₃ is phenyl and n is 1 or the D or L stereoisomer.
20. The use of claim 1 or 2 wherein R is benzyl, R₁ is methyl, R₂ is hydrogen, 15 R₃ is (lower alkoxy) lower alkyl, and n is 1.
21. The use of claim 1 or 2 wherein R is benzyl, R₁ is methyl, R₂ is hydrogen, R₃ is methoxymethyl, and n is 1 or the D or L stereoisomer;
- 20 R is benzyl, R₁ is t-butyl, R₂ is hydrogen, R₃ is methyl and n is 1 or the D or L stereoisomer;
- R is benzyl, R₁ is methyl, R₂ is hydrogen, R₃ is (2-thiomethyl)ethyl and n is 1 or the D or L stereoisomer;
- R is (3-fluoro)benzyl, R₁ is methyl, R₂ is hydrogen, R₃ is methyl and n is 1 or the D or L stereoisomer;
- 25 R is (3-methoxy)benzyl, R₁ is methyl, R₂ is hydrogen, R₃ is methyl and n is 1 or the D or L stereoisomer;
- R is benzyl, R₁ is methyl, R₂ is (3-thienyl), R₃ is hydrogen and n is 1 or the D or L stereoisomer;
- R is benzyl, R₁ is methyl, R₂ is (2-thienyl), R₃ is hydrogen and n is 30 1 or the D or L stereoisomer;
- R is benzyl, R₁ is methyl, R₂ is (2-furyl), R₃ is hydrogen and n is 1 or the D or L stereoisomer;

R is benzyl, R₁ is methyl, R₂ is (2-pyrrolyl), R₃ is hydrogen and n is 1 or the D or L stereoisomer;

R is benzyl, R₁ is methyl, R₂ is ethoxy, R₃ is hydrogen and n is 1 or the D or L stereoisomer; or

5 R is benzyl, R₁ is methyl, R₂ is methoxy, R₃ is hydrogen and n is 1 or the D or L stereoisomer.

22. The use of claim 1 or 2 wherein the compound is in the D isomer form.

10 23. The use of claim 1 or 2 wherein the medicament comprises a pharmaceutically acceptable carrier.

24. The use of claim 23 wherein the medicament is suitable for oral administration.

15

25. The use of claim 23 wherein the medicament is suitable for intrathecal administration.

26. The use of claim 23 wherein the medicament is suitable for intravenous
20 administration.

27. The use of claim 23 wherein the the medicament is suitable for administration by inhalation or insufflation.

25 28. The use of claim 1 wherein R₂ is hydrogen; and R₃ is 2-furyl, 2-pyrrolyl, 1-pyrazolyl, 2-oxazolyl, 2-thiazolyl, pyridyl, pyrazinyl, or pyrimidinyl.


29. The use of claim 1 or 2 wherein R₂ is hydrogen; R₃ is NR₄OR₅; R₄ is hydrogen or lower alkyl; and R₅ is lower alkyl.

30

30. The use of claim 1 or 2 wherein R is benzyl, substituted with at least one electron withdrawing substituent or at least one electron donating substituent.

31. The use of claim 1 wherein the compound is (R)-*N*-benzyl-2-acetamido-3-methoxypropionamide, or a pharmaceutically acceptable salt thereof.

32. A therapeutic method comprising treating a human afflicted with, or at risk of stroke, by administering an effective amount of a compound of formula (I):



10 wherein

R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, lower cycloalkyl, lower cycloalkyl (lower alkyl), and R is unsubstituted or is substituted with at least one electron withdrawing group, or electron donating group;

15

R₁ is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, (lower alkyl) heterocyclic, heterocyclic (lower alkyl), lower cycloalkyl, lower cycloalkyl (lower alkyl), each unsubstituted or substituted with an electron donating group or an electron withdrawing group

20 and

R₂ and R₃ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclic, heterocyclic (lower alkyl), (lower alkyl) heterocyclic, lower cycloalkyl, lower cycloalkyl (lower alkyl), SO₃⁻, or Z-Y wherein R₂ and R₃ may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group;

25

Z is O, S, S(O)_n, NR₄, PR₄ or a chemical bond;

Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic (lower alkyl), (lower alkyl)heterocyclic cycloalkyl, cycloalkyl (lower alkyl) and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond;

30

or ZY taken together is $\text{NR}_4\text{NR}_5\text{R}_7$, NR_4OR_5 , ONR_4R_7 , OPR_4R_5 , PR_4OR_5 , SNR_4R_7 , NR_4SR_7 , SPR_4R_5 , PR_4SR_7 , $\text{NR}_4\text{PR}_5\text{R}_6$, $\text{PR}_4\text{NR}_5\text{R}_7$, $\text{NR}_4\text{C(O)R}_5$, SC(O)R_5 , $\text{NR}_4\text{CO}_2\text{R}_5$, SCO_2R_5 , $\text{NR}_4\text{C(O)R}_5\text{R}_6$, $\text{NR}_4\text{C(O)NR}_5\text{S(O)}_a\text{R}_6$, $\text{NR}_4\text{C(S)R}_5\text{R}_6$, $\text{NR}_4\text{C(=Q)MNR}_5\text{C(=A)OR}_6$, or C(S)NH_2 ;

- 5 R_4 , R_5 and R_6 are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl, or lower alkynyl, wherein R_4 , R_5 and R_6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;

R_7 is R_6 , COOR_6 , or C(O)R_6 ;

- 10 R_8 is hydrogen or lower alkyl, or aryl (lower alkyl), and the aryl or alkyl group may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;

A and Q are independently O or S;

M is an alkylene chain containing up to 6 carbon atoms or a

- 15 chemical bond;

n is 1-4; and

a is 1-3;

or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/14449

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/165

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 378 729 A (KOHN ET AL.) 3 January 1995 cited in the application -----	

☐

Further documents are listed in the continuation of box C.

☒

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

16 October 1998

Date of mailing of the international search report

22/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/14449

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5378729 A	03-01-1995	AT 161824 T	15-01-1998
		AU 657985 B	30-03-1995
		AU 2162192 A	08-01-1993
		CA 2110693 A	10-12-1992
		DE 69223965 D	12-02-1998
		DE 69223965 T	30-04-1998
		EP 0592490 A	20-04-1994
		JP 6510985 T	08-12-1994
		US 5654301 A	05-08-1997
		WO 9221648 A	10-12-1992
		AU 641160 B	16-09-1993
		AU 5519590 A	28-02-1991
		CA 2017217 A	19-11-1990
		EP 0400440 A	05-12-1990
		JP 3506045 T	26-12-1991
		PT 94103 A, B	08-01-1991
		WO 9015069 A	13-12-1990
		DE 3786865 A	09-09-1993
		DE 3786865 T	09-12-1993
		DK 526087 A	08-04-1988
		EP 0263506 A	13-04-1988
		ES 2058085 T	01-11-1994
		IE 61437 B	02-11-1994
		JP 2580196 B	12-02-1997
		JP 63132832 A	04-06-1988
		PT 85869 B	31-07-1990
		AU 596573 B	10-05-1990
		AU 5371186 A	21-08-1986
		DK 72686 A	16-08-1986
		EP 0194464 A	17-09-1986
		IE 58422 B	22-09-1993
		JP 1972065 C	27-09-1995
		JP 6104649 B	21-12-1994
		JP 61200950 A	05-09-1986
		PT 82032 B	01-07-1988